ReviewHeliyon2025
Advanced photoluminescent nanomaterials for targeted bioimaging of cancer cells.
Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Synthesis of terbium and silica modified graphene quantum dots for targeted bioimaging of breast cancer cells using folate receptors.Scientific reports · 2025Article
- Current Research in Drug-Free Cancer Therapies.Bioengineering (Basel, Switzerland) · 2025Review
- Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The investigation of changes in the membrane of cancer cells holds great potential for biomedical applications. Malignant cells exhibit overexpression of receptors, which can be used for targeted drug delivery, therapy, and bioimaging. Targeted bioimaging is one the most accurate imaging methods with a non-invasive nature, allowing for localization of the malignant cell without disrupting cellular integrity. Also, bioimaging has the potential to enhance the quality of established imaging techniques like magnetic resonance imaging (MRI). The utilization of nanoparticles in targeted bioimaging enhances the imaging quality and efficiency. Biocompatible nanoparticles can easily penetrate cell membranes, while they can be readily functionalized on their surfaces toward cell receptors. This study reviews reports on the application of new advanced photoluminescent materials for targeted bioimaging using the cell membrane receptors. Also, the limitations and advantages of the application of nanoparticles have been reviewed along with the clinical consideration of their uses in bioimaging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.